Aberrant expression of RSK4 in breast cancer and its role in the regulation of tumorigenicity

12Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Breast cancer is the most frequently diagnosed cancer in both more and less economically developed countries and remains the leading cause of cancer-related death in women worldwide. In this study, to explore the expression and pathological role of RSK4 in breast cancer progression, we demonstrated that RSK4 expression was significantly decreased in breast cancer cells and tissues, and the overexpression of RSK4 in MDA-MB-231 cells inhibited cell migration and invasion. In a mouse model experiment, overexpression of RSK4 in mice further confirmed its critical role in regulating breast cancer tumorigenicity. The regulatory role of RSK4 in breast cancer development was mediated by AKT and extracellular signal-regulated kinase (ERK) signaling pathways and the expression of RSK4 was altered by DNA methylation in promoter regions. These results provide important insight into the role of RSK4 in cancerogenesis and may help to improve the prevention, diagnosis and treatment of breast cancer.

Cite

CITATION STYLE

APA

Jiang, Y., Ye, X., Ji, Y., Zhou, X., Yang, H., Wei, W., & Li, Q. (2017). Aberrant expression of RSK4 in breast cancer and its role in the regulation of tumorigenicity. International Journal of Molecular Medicine, 40(3), 883–890. https://doi.org/10.3892/ijmm.2017.3069

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free